Key result
Evolocumab shows no effect on cognitive decline compared to placebo over 2.2 years.
Why the study?
The impact of evolocumab added to statin therapy on patient-reported cognition in a large population with atherosclerotic cardiovascular disease was not fully described.
Does evolocumab cause patient-reported cognitive decline in patients with atherosclerotic cardiovascular disease on statin therapy?
RCT (n=22,655)
double-blind
randomized
Does evolocumab cause patient-reported cognitive decline in patients with atherosclerotic cardiovascular disease on statin therapy?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These data confirm the neurocognitive safety of intensive LDL-C reduction with evolocumab, while simultaneously reducing recurrent cardiovascular events in high-risk patients, and suggest that very low achieved LDL-C levels may be safely targeted for high-risk patients.”
“there's no signal of impaired cognition with PCSK9 inhibitors compared to placebo in this patient population”
The addition of evolocumab to statin therapy does not negatively impact patient-reported cognition over a median of 2.2 years, even among those achieving LDL-C <20 mg/dl.
Background: The EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that evolocumab added to a background statin did not affect cognitive performance in a subset of 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With Elevated Risk). Objectives: The authors describe patient-reported cognition in the entire FOURIER trial using a self-survey. Methods: FOURIER was a randomized, double-blind, placebo-controlled trial involving patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels ≥70 mg/dl or non-high-density cholesterol ≥100 mg/dl despite statin therapy. At the final visit, patients completed a 23-item survey on memory and executive domains from the Everyday Cognition (ECog) scale. Patients compared their levels of everyday function at the end of the trial with their levels at the beginning and scored as 1 (no change or improvement), 2 (occasionally worse), 3 (consistently little worse), or 4 (consistently much worse). ECog scores were compared by the 2 randomized treatment arms and by achieved LDL-C at 4 weeks. Results: A total of 22,655 patients completed ECog after a median duration of 2.2 years. The proportions of patients reporting cognitive decline (ECog score ≥2) at the end of the study were similar for placebo versus evolocumab, both for total score 3.6% versus 3.7% (p = 0.62) and for subdomains (memory, 5.8% vs. 6.0%; total executive, 3.6% vs. 3.7%). The proportion of patients reporting a decline in total cognitive score was similar among the 2,338 patients who achieved very low LDL-C levels (<20 mg/dl) compared to the 3,613 patients with LDL-C ≥100 mg/dl (3.8% vs. 4.5%, p = 0.57). Conclusions: The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dl.
No takes yet. Share an insight, caveat, or question.
Gencer et al. (2020) conducted an RCT in atherosclerotic cardiovascular disease and elevated LDL-C despite statin therapy (n=22,655). Evolocumab vs. Placebo was evaluated on patient-reported cognitive decline (ECog total score ≥2) (p=0.62). Evolocumab added to statin therapy did not affect patient-reported cognitive decline compared to placebo over a median of 2.2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: